Quintessence Publishing: Events

Share Page:

Thursday, June 6
Friday, June 7
Saturday, June 8
Sunday, June 9

Osteoporosis: The Oral-Systemic Connection

Robert E. Marx
Saturday, February 8
2:00 pm - 2:45 pm

Notice: Undefined variable: room in /home/quintpub/public_html/eventManagement/templates/boston/lecture.php on line 145

Osteoporosis is an age- and hormone-related thinning of the cancellous trabeculae and cortex, which structurally weakens bone at varying degrees and thus makes it more prone to fracture. Osteoporosis involving the jaws causes a thinning of their bony trabeculae and cortex, just as it does in other bones; this is often referred to as type III or type IV bone. It is much more difficult to gain primary stability during implant placement, and there is reduced osseointegration potential. However, the greatest impact of osteoporosis on the jaws is a condition now known as drug-induced osteonecrosis of the jaws (DIONJ). All oral and intravenous bisphosphonates marketed for osteoporosis, as well as oral denosumab, have caused DIONJ. Yet, alendronate (Fosamax) because of its potency and a recommended dose that is twice that of other oral bisphosphonates, has been responsible for more than 90% of all reported cases and has even caused femur fractures. It is the osteoporosis drug of greatest oral impact.

Robert E. Marx, DDS, is a professor of surgery and chief of the Division of Oral and Maxillofacial Surgery at the University of Miami Miller School of Medicine. His areas of research include the use of hyperbaric oxygen following radiation therapy, the development of platelet-rich plasma, and the relationship between smoking and carcinogenesis. Dr Marx has received numerous awards, including the Harry S. Archer Award, the William J. Gies Award, the Paul Bert Award, and the Donald B. Osbon Award. His first textbook, Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment (Quintessence, 2002), won the American Medical Writers Associationís Medical Book of the Year Award for 2003.